KLK4 and hereditary angioedema: The development of targeted therapies, such as plasma-derived and recombinant C1 inhibitor concentrates, bradykinin receptor antagonists, and plasma kallikrein inhibitors, has revolutionized both acute and prophylactic care for HAE patients.